Pulmonext 5mg Tablet is a prescription-only medicine used in the management of Pulmonary Arterial Hypertension (PAH) — a condition characterized by high blood pressure in the arteries of the lungs. Classified as an endothelin receptor antagonist (ERA), Ambrisentan works by blocking the action of endothelin-1, a natural substance that causes blood vessels to narrow. This helps in relaxing and widening the pulmonary arteries, thereby reducing the pressure and improving the heart’s ability to pump blood efficiently.

This medication significantly improves:

• Exercise capacity

• Breathing ability

• Quality of life in patients with PAH (WHO Group I)

Pulmonext 5mg Tablet is especially beneficial in WHO Functional Class II and III PAH patients, where it helps delay clinical worsening and disease progression. It may be used alone or in combination with other PAH medications like phosphodiesterase-5 inhibitors (e.g., Tadalafil) or prostacyclin analogs, depending on the patient’s clinical profile.

The tablet is well-absorbed orally and has a favorable side effect profile compared to other ERAs, particularly with a lower risk of liver toxicity. It is usually taken once daily, making it a convenient, long-term option for managing this serious and progressive disease.